Key questions about RudaCure
Source-linked answers about RudaCure, the RuCIA platform, RCI001 development and partnering enquiries.
Public information reviewed:
What is RudaCure?
RudaCure is a Korean drug discovery company founded in 2018. It targets membrane proteins, including ion channels and GPCRs (G protein-coupled receptors), to develop therapeutics for dry eye disease, chronic pain, psoriasis and rare neurological disease.
Sources and details
What is RuCIA?
RuCIA (RudaCure Ion Channel Innovative Assessment) is RudaCure's drug discovery platform. It connects AI-based molecular prediction, structure-based design and molecular dynamics simulations with electrophysiology and pharmacology evaluation to investigate drug candidates.
Sources and details
What is RCI001 and what is its development stage?
RCI001 is an investigational ophthalmic drug candidate for dry eye disease. According to company announcements, it has received US FDA (Food and Drug Administration) Phase 2 IND (Investigational New Drug) clearance and Korean Phase 2 clinical trial plan approval. The Korean approval was announced on September 22, 2026. Permission to conduct a trial is not marketing approval or proof of efficacy in patients.
Sources and details
Which programmes are listed in the public pipeline?
The pipeline page lists RCI001 for human dry eye disease, RCI001AH for veterinary dry eye, RCI002 for chronic pain via intra-articular administration, RCI003 for psoriasis, and RC0125 AAV (adeno-associated virus) gene therapy. The detailed pipeline page describes the stage and milestones of each candidate.
Sources and details
Where can I find research publications and patents?
The Publications page lists research papers and patents, with links to papers and country-specific filing and grant information. Preclinical research findings should be distinguished from results demonstrated in clinical trials.
Sources and details
What CRO services does RudaCure offer?
RudaCure describes CRO (Contract Research Organization) services including pharmacology evaluation, in vivo and in vitro assessment, ion-channel screening and ocular-disease animal models. Contact the service team to discuss study scope and execution requirements.
Sources and details
How can I contact RudaCure about partnering, licensing or investment?
The Contact page accepts partnership, licensing, investment and CRO enquiries. The business development email is sh.kim@rudacure.com. Headquarters are at Building 1, Room 302, 9 Songdo Mirae-ro, Yeonsu-gu, Incheon, Korea. The Seoul office is at Room 1001, 145 Gasandigital 1-ro, Geumcheon-gu, Seoul, Korea.